



**SHATTUCK**  
LABS

NEWS RELEASE

# Shattuck Labs Announces Participation in Upcoming 6th Annual Evercore ISI HealthCONx Conference

2023-11-14

AUSTIN, TX & DURHAM, NC, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in the 6<sup>th</sup> Annual Evercore ISI HealthCONx Conference being held November 28-30, 2023.

## **Presentation Details**

Conference: 6<sup>th</sup> Annual Evercore ISI HealthCONx Conference  
Format: Fireside chat with covering analyst, Jonathan Miller, Ph.D.  
Presenter: Dr. Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer  
Date: November 29, 2023  
Time: 9:10 a.m. ET

A live webcast of the fireside chat will be available on the [Events & Presentations](#) section of the Company's website. A replay of the webcast will be archived for up to 90 days following the presentation date.

## **About Shattuck Labs, Inc.**

Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ("ARC®"), platform are designed to simultaneously inhibit checkpoint molecules and activate costimulatory molecules with a single therapeutic. The company's lead SL-172154 (SIRPα-Fc-CD40L) program, which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in multiple Phase 1 trials. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: [www.ShattuckLabs.com](http://www.ShattuckLabs.com).

**Investor & Media Contact:**

Conor Richardson  
Vice President of Investor Relations  
Shattuck Labs, Inc.  
[InvestorRelations@shattucklabs.com](mailto:InvestorRelations@shattucklabs.com)

Source: Shattuck Labs, Inc.